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What’s already known about this topic? 
• Far too many outcomes are used in dermatological clinical trials that hamper meaningful 
comparisons that in turn affects care for dermatology patients. 
• Core outcome sets are an agreed standardized collection of outcomes that should be included in all 
clinical trials for a specific health condition. 
• The Core Outcome Set Initiative within the Cochrane Skin Group (CSG-COUSIN) was established 
to support the development of core outcome sets (COS) in dermatology. 
 
What does this study add? 
• The second meeting of CSG-COUSIN took place in 2017 and included updates from eleven core 
outcome projects covering a wide range of skin diseases from acne to melanoma. 
• Research gaps identified included the need to develop more guidance on how to appropriately define 
the focus of a COS, how to identify the core domains, how to best involve patients, and which are the 
most useful decision rules within Delphi surveys when developing COS. 
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• The meeting concluded that some common outcome domains may be applicable to dermatological 
diseases in general.
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Summary 
Results of clinical trials are the most important information source for generating external clinical 
evidence. The use of different outcomes across trials, which investigate similar interventions for 
similar patient groups, significantly limits the interpretation, comparability and clinical application of 
trial results. Core outcome sets (COS) aim to overcome this limitation. COS are an agreed 
standardized collection of outcomes which should be measured and reported in all clinical trials for a 
specific clinical condition. The Core Outcome Set Initiative within the Cochrane Skin Group (CSG-
COUSIN) supports the development of core outcomes in dermatology. In the second CSG-COUSIN 
meeting held in 2017, eleven COS development groups working on skin diseases presented their 
current work. The presentations and discussions identified the following overarching methodological 
challenges for COS development in dermatology: it is not always easy to define the disease focus of a 
COS; the optimal method for outcome domain identification and level of detail needed to specify such 
domains is challenging to many; decision rules within Delphi surveys need to be improved; 
appropriate ways of patient involvement are not always clear. In addition there appear to be outcome 
domains that may be relevant as potential core outcome domains for the majority of skin diseases. The 
close collaboration between methodologists in the Core Outcome Set Initiative and the international 
Cochrane Skin Group has major advantages for trialists, systematic reviewers, and COS developers. 
 
 
 
 
Key words: Core outcome set, clinical trial, systematic review, dermatology, Cochrane Collaboration 
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Background 
Results of clinical trials are the most important information source for generating external clinical 
evidence for evidence based medicine and care.1 Threats to internal and external validity of clinical 
trials are well known and these limitations must be adequately taken into account when interpreting 
and summarizing trial results.2,3 The increase in numbers of published clinical trials has revealed a 
further challenge that has received increasing attention during the last decades: the multitude and poor 
comparability of outcomes that are used and reported.
4
 
Non-comparable outcomes across trials investigating similar interventions for similar patient 
groups cause a number of problems for the interpretation and clinical application of trial results. The 
use of different outcomes across trials makes it impossible to compare treatment effects between 
studies. Even if the same outcome domain is captured in different trials (e.g. pain, clinical signs of 
disease severity), there are still diverse ways to measure this phenomenon or construct. This problem 
occurs in all fields of health and medical care but also in dermatology: at least 20 different named 
outcome measurement instruments have been published to measure atopic dermatitis,5 11 outcome 
measurement instruments have been identified for measuring aspects of vitiligo,
6
 46 instruments for 
measuring repigmentation alone in vitiligo,
7
 53 for measuring the clinical severity of psoriasis,
8
 and 30 
for measuring hidradenitis suppurativa in clinical trials.9 More than 111 clinical scales are available for 
measuring skin ageing.
10
 Different instruments measuring the same construct produce different 
numerical expressions which cannot be pooled in meta-analyses. 
In addition, outcome measurement instruments themselves need to meet quality criteria 
including validity, reliability, responsiveness,
11
 and relevance to the target population.
12
 Results of 
systematic reviews indicate that the reliability and validity of the majority of applied instruments in 
dermatology are not supported by adequate evidence.5,6,8-10 The choice of the best and most relevant 
outcomes is not only a challenge for trialists, but also for systematic reviewers. Systematic reviews 
should include all outcomes that are meaningful and relevant to clinicians, patients, the general public, 
administrators and policy makers. In the 64 Cochrane Skin Group (CSG) reviews published up to 
January 2015, 402 outcomes were predefined by the review authors. Of these, 33% were not addressed 
in any individual trial.13 The number of outcomes reported in the individual trials but not included by 
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the systematic reviewers is unknown but probably much higher. This indicates that there seems to be 
significant mismatch between outcomes considered important by Cochrane review authors (that 
include patients) and outcomes measured and reported in trials. 
 
Core outcome sets 
One solution to overcome these difficulties is standardization of outcomes and outcome 
measurements. A core outcome set (COS) is an agreed standardized set of outcomes that should be 
measured and reported, as a minimum, in all clinical trials in a specific disease or trial population. 
They consist of outcome domains and corresponding measurement instruments.11 Domains are broader 
aspects or concepts of a disease indicating “what” to measure (e.g. disease severity, pain). 
Measurement instruments are needed to measure the particular domain and indicate “how” to measure 
(e.g. scales, classifications).
11,14
 The Outcome Measures in Rheumatoid Arthritis Clinical Trials 
(OMERACT) initiative was the first group to systematically develop and promote core outcomes use. 
Today, there is growing interest in COS development with a corresponding increase in the volume of 
methodological research and guidance.
11,15-18
 The Core Outcome Measures in Effectiveness Trials 
(COMET) initiative provides a platform for scientific exchange and supports methodological research 
in this area. COMET also hosts a database covering planned and published COS projects.19 Recently, 
the Core Outcome Set-Standards for Reporting (COS-STAR) Statement was published.
17
 However, 
compared to clinical trial methodology, the science and practice of COS development is still under 
developed and the field is continuing to tackle a number of fundamental methodological questions and 
uncertainties. The purpose of this meeting report is to summarize these challenges in relation to COS 
in dermatology in order to identify and prioritise possible directions for future research and 
development. 
 
Cochrane Skin Group - Core Outcome Set Initiative 
The Harmonizing Outcome Measures for Eczema (HOME) initiative set out in 2008 to develop a COS 
for atopic dermatitis trials and was the first COS initiative in dermatology.
20,21
 The HOME initiative 
developed the HOME roadmap14 to be used as a methodological framework for COS development. In 
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addition to other existing guidance,
17,22
 the HOME roadmap is being used by many COS initiatives in 
dermatology.9,23,24 Because outcome selection is so fundamental for clinical trials and systematic 
reviews supported by the Cochrane Collaboration, two of the report authors (HCW and JS) established 
the Core Outcome Set Initiative (COUSIN) within the Cochrane Skin Group (CSG) in 2014. The 
CSG-COUSIN is an international multidisciplinary group that strives to support the development and 
to strengthen the quality of COS development in dermatology. The inaugural meeting took place in 
2015 in Dresden (Germany) within the CSG annual meeting.
13
 CSG-COUSIN consists of a 
management team based in Dresden (Germany), a methods group, and a number of disease-specific 
COS project groups. The management team coordinates CSG-COUSIN and provides organisational 
and technical support for the methods and project groups. Since the first meeting a homepage was 
launched,25 a meeting report published,13 newsletters prepared, and visibility and awareness created 
(e.g. poster, flyer, or presentations at dermatology conferences). The methods group provides 
methodological support and internal peer review for CSG-COUSIN project groups, conducts 
methodological studies on outcomes research and COS development, and sets up quality standards for 
COS development and implementation processes. The COUSIN group has also developed a practical 
guidance document how to develop COS based on the HOME roadmap.
26
 CSG-COUSIN project 
groups work on the development and implementation of specific COS in dermatology. Since 
inception, 14 COS development projects are now working with CSG-COUSIN.
25
 In January 2017, the 
second CSG-COUSIN meeting took place within the two-day CSG annual meeting at the Department 
of Dermatology and Allergy at the Charité-Universitätsmedizin Berlin (Germany) hosted by two of the 
report authors (JK, AN). The entire first day was dedicated to CSG-COUSIN topics, the second day 
covered methodological topics of the CSG in general. 
 
Aims of the meeting 
The primary objective was the presentation and discussion of the current status of COS development 
in the different COS project groups in order to share learning of how to overcome common logistical 
and methodological hurdles. Groups were requested to present their current work and achievements 
but - most importantly - to identify challenges and problems. Additionally, the meeting aimed to 
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present and discuss current standards of COS reporting and quality criteria / quality assurance related 
to COS development so that the work of the group could be aligned to the latest relevant research in 
the field. Furthermore, the meeting aimed to strengthen the cooperation between clinical researchers, 
trialists, methodologists, COS developers and systematic reviewers involved in Cochrane reviews. 
Based on the identified problems and opportunities a work plan for the next year was to be developed. 
 
Meeting participants 
Dermatologists, methodologists, systematic reviewers and researchers with an interest in evidence-
based dermatology and COS development attended. The majority were from the CSG. Patient 
representatives were present and participated in the discussions. However, there was no special form 
of patient involvement at this first day of the CSG annual meeting. Patients always participated 
actively in the individual COS development groups. 
 
Meeting content 
After an introduction, a keynote lecture by Jamie Kirkham from the COMET group, and critical 
reflection on the development of CSG-COUSIN, 11 individual COS groups presented their current 
work status (Table 1). Each presentation included a summary of what has been done so far, 
preliminary results and challenges. The identified challenges were discussed extensively with the 
whole group. The discussion was led by a moderator and emerging issues documented on flip chart 
papers visible for all. During this process overarching methodological challenges that were relevant 
for COS development in general were identified, and these are summarized below. 
 
Health problem and population 
The definitions of the health problem, target populations, healthcare setting and likely interventions 
are crucial first steps in COS domain development14,17, yet it is not always clear how this should be 
done. For instance it was discussed, whether separate COS should be developed for children and 
adults and for induction and maintenance treatments for people with chronic skin diseases. Do COS 
domains for melanoma stage 1 differ from other melanoma stages? Is a COS for nail psoriasis justified 
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or is it just a subset of psoriasis patients in general? Do different types of interventions (e.g. 
repositioning vs. special support surface for pressure ulcer prevention) in pressure ulcer prevention 
address different outcomes, requiring intervention-specific COS? On the other hand, it was argued that 
for some skin conditions, different interventions usually have the same aim thus justifying identical 
domains. The overall question of when to split a skin disease or treatment into subgroups or when to 
treat this as one entity was discussed.  
 
Domain identification 
In the early stages of a COS development project all possible disease domains must be identified 
first.
14,26
 In addition to qualitative approaches systematic literature searches are another way for 
identifying domains. It was discussed whether the consideration of published clinical trials is sufficient 
for domain identification. When choosing core outcomes from existing clinical trials other important 
domains may be missed. In accordance with current methodological guidance
16
 it was agreed that 
looking at published clinical trials is necessary but not sufficient. A discussion arose which other 
publication types (e.g. qualitative studies) need to be considered. It was agreed that the domain 
identification should not only be influenced by the assumed or known existence of measurement 
instruments. 
 A major challenge for nearly all groups was how to extract and/or to define domains based on 
the literature. Methodological guidance how to develop COS domains is available
11,17,18,22
 but an 
unsolved problem is deciding how broad or narrow a domain should be. Are all clinical signs of a 
cutaneous disease considered together a domain or is each sign (e.g. erythema, scaling, inflammatory 
lesions) a domain? When in the process should what be summarized by whom? Is ‘skin ageing’ a true 
domain? Moreover, it is unclear how many domains should be included in the subsequent Delphi 
study and how many outcome domains should be included in a COS. Slightly different definitions of 
‘domains’ and ‘outcomes’ in existing methodological frameworks further contribute to uncertainty. 
Conceptual difficulties regarding domain definition and identification also exist in established 
methodological frameworks
27
 and they may be context or discipline specific. Discussions showed that 
the level of abstraction of core domains in dermatology is not clear. In addition there appear to be 
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outcome domains that may be applicable for the majority of skin diseases. Furthermore, guidance is 
needed for the timing of outcome assessment of these domains. 
 
Instruments 
Heterogeneity generally concerns variation between different outcome measurements used. However, 
in some diseases (e.g. nail psoriasis) wide variation within outcome measurements with the use of 
many different versions of the same outcome measurement has been detected. These different versions 
should be mentioned as separate instruments in the process towards COS development. The 
methodological appraisal and selection of measurement instruments in general was regarded as 
challenging. One main reason seems to be that widely used instruments often do not meet criteria for 
good measurement properties.11 Development of new instruments is a major, time and resource 
intensive task which is also not easy to be accomplished. This led to the unanswered question what to 
do with domains for which appropriate instruments are missing.  
 
Decision rules during the Delphi rounds and disagreement between stakeholders 
The Delphi technique is considered as the current methodological standard for outcome domain and 
outcome measurement instrument selection and prioritization prior to further face to face consensus 
work. Although methodological guidance is available
22
 
28
, the predefined consensus criteria and 
scoring system rules were discussed in more detail. Currently, five, seven, and nine item scales 
ranging from 1 (= not essential/important) to 9 (= absolutely essential/important) are widely used to 
measure agreement between Delphi study participants in COS projects. Decision rules are often based 
on cut-offs (e.g. a certain proportion of responses between 7 and 9).
21,29
 This format is based on the 
RAND/UCLA Appropriateness Method30 and also proposed by GRADE.31 However, while the 
RAND/UCLA method proposes a number of stricter and relaxed rules for determining agreement and 
disagreement, these are not applied in current COS initiatives. RAND/UCLA proposed agreement and 
disagreement rules were designed for 9-member panels only,30 whereas in COS Delphi groups the 
number of participants is much higher. Therefore, using strict thresholds to decide whether COS 
domains are kept or left out is arbitrary.32 This procedure also questions the usefulness of the full 
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information content which is obtained from the entire 1 to 9 scale. It is always recommended to use 
the full range of information from rating scales otherwise they are not needed in that specific 
format.33,34 Consequently, the Core outcome Set for Congenital Vascular Malformations (OVAMA) 
group used dichotomous questions in a consensus meeting after completing three Delphi rounds by 
simply asking participants whether they think each domain should be included or not. This approach 
was considered as a possible alternative to the current standard of the 9-item scale method used by the 
majority of COS developers. However, a dichotomous approach may be also associated with loss of 
information which might be valuable for discussion should the consensus process involve a consensus 
meeting. 
 Closely related to decision rules was the question of how to deal with disagreements between 
stakeholder groups, especially physicians vs. patients was discussed. Examples were presented where 
there was complete disagreement between both groups and possible solutions were explored. The 
vitiligo outcomes initiative has encountered a difficulty in achieving consensus amongst stakeholders 
groups on how best to measure repigmentation - one of the essential outcomes. One idea was that 
disagreements might be solved in a structured face-to-face discussion. The way in which results are 
presented are likely to influence subsequent decision making. The question arose of whether patients 
should have a veto on choosing a particular domain if the patient perspective is considered to be most 
important. 
 
Patient involvement 
Involving patient representatives during the COS development process was regarded as important. 
Patient and carer involvement is crucial for domain identification for example. Guidance on how to 
involve patients in research in general35 is available and how to involve patients and service users 
using qualitative COS development methods is emerging
16
 but there was uncertainty on how best to 
ensure meaningful patient involvement. Possible options include using existing patient groups (e.g. 
COMET’s People and Patient Participation Involvement and Engagement (PoPPIE) working group). 
Pre-meetings and patient training sessions before participation in meetings and Delphi studies were 
recommended. Patients may find it especially difficult to understand the concepts within eDelphi 
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studies. Face-to-face meetings with patients were considered to be empowering for patients. Online 
meetings using advanced webinar software may enable easier participation without the costs and 
burden of travelling. A general concern was whether involved patients are sufficiently representative 
for a whole patient group. Patients are usually highly selected, e.g. they must be willing to actively 
participate, they need to speak English, must have the possibility and willingness to travel, or must be 
familiar with online technology. This leads to a systematic exclusion of particular patient groups. 
Overall, there is a difference between involving patients in the COS development project as partners or 
as participants (e.g. in a Delphi study). 
 
Are there common domains within dermatology? 
It was clear from the presentations that there were common outcome domains between different skin 
diseases (e.g. physical signs and symptoms, global severity assessment by a physician/healthcare 
professional, or satisfaction with treatment as was included in HISTORIC and ACORN outcome 
selection). Recently, OMERACT proposed a conceptual framework of core areas for outcome 
measurements in intervention studies
36
 and the idea was proposed that there may be dermatology 
specific outcome domains which are applicable to the majority of COS of clinical trials in skin 
diseases. The possibility of creating a long list that covers all possible domains and from which each 
group could make a selection from was also discussed. This proposal will be further explored and will 
become the subject of a future CSG-COUSIN project. 
 
Funding 
COS development work is not generally funded by public funding bodies. A lack of appropriate 
funding was regarded as one important cause for a comparably slow progress in many COS 
development initiatives. Some delegates mentioned that they had been successful in obtaining funding 
for PhD students to work on COS studies. Generally, it was believed that industry may also have an 
intrinsic interest in funding the development of most relevant COS but identifying an appropriate 
funding model that was free of possible bias was unclear. 
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Conclusions and outlook 
COS are needed to improve evidence-based dermatology and patient care. Therefore, it is important to 
address this topic appropriately using high quality methods. Inappropriately developed and published 
COS are potentially no better than no COS.
26
 CSG-COUSIN exists to support and to promote high 
quality COS in dermatology. All meeting participants and groups expressed their interest and need for 
continuing interaction and discussions. The close association between COS development and the CSG 
has many advantages. Systematic reviewers must consider COS once they exist. Even if a COS is not 
available CSG-COUSIN provides the platform to connect systematic reviewers with COS groups. 
COS development groups are strongly advised to liaise with Cochrane review authors to ensure their 
insight into published outcomes and trials can be utilised when developing COS.  In order to 
implement this, the CSG editorial base and the CSG-COUSIN will develop better links between CSG 
review authors and COS groups before starting work. Further collaboration exists for instance with 
other groups interested in developing patient-centered outcomes such as The International 
Dermatology Outcome Measures (IDEOM) Group37,38 in the Hidradenitis Suppurativa Core Outcomes 
Set International Collaboration (HISTORIC).
32
 
 During the meeting more questions than answers were raised. We are also aware that some 
issues such as the challenges of COS implementation were not addressed.39 Patient and public 
involvement could have been stronger and more structured at our meeting which is something that will 
be addressed at the next CSG-COUSIN meeting. COS development is a complex and challenging task. 
Established methodological frameworks exist11,16,18,36 but some steps and decisions during the process 
are more subjective than others. Further standardization seems to be one way to establish quality 
standards. One attendee asked whether COS are reproducible i.e. whether different groups using 
identical information would come up with similar domains and instruments. While it would be 
extremely challenging to do such comparisons it is not impossible and it might answer the question 
how robust current COS development methods are. 
One main conclusion of the meeting was that the CSG-COUSIN methods group needs to 
develop requirements for the development of high quality COS in dermatology. Based on existing 
guidance14,17,18 such practical standards will include blueprint protocols, internal peer review, and 
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standardized interaction between COS groups and corresponding Cochrane review groups. These 
processes and documents will be developed by the methods group by the end of 2017 and introduced 
at the next CSG-COUSIN meeting in Amsterdam in January 2018. Methodological guidance and 
standardized procedures throughout the different stages of COS development
14
 have been identified as 
a critical prerequisite for CSG-COUSIN to meet their primary aim of developing high quality COS. 
The other short term goal for CSG-COUSIN to complete prior to the next meeting in 2018 is to better 
integrate the development of high quality reviews within the Cochrane Skin Group with COS 
development through the CSG-COUSIN collaboration. 
The CSG-COUSIN is not externally funded and relies on the voluntary work of the people 
involved. CSG-COUSIN is an international group with a clear and exclusive focus on developing core 
outcome sets in dermatology according to high methodological standards and is firmly embedded with 
the international Cochrane Skin Group that produces high quality systematic reviews of primary 
research. We invite interested researchers, clinicians, methodologists, patients, payers, industry, and 
regulators to participate and to contribute to this exciting new initiative in dermatology and we 
welcome proposals from groups wishing to develop COS in skin diseases not currently being 
developed within CSG-COUSIN. 
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Table 1. Core outcome set development in dermatology (January 2017) 
Initiative Presenter Work progress 
1. 
Preparation 
2. 
Protocol 
3. Outcome 
domains 
4. Outcome 
measurements 
5. 
Dissemination 
Developing a Core 
Outcome Set for 
Melanoma trials 
Prof. Spuls (The 
Netherlands)   In progress In progress - 
IMPROVED - 
Core Outcome Set 
for the Appearance 
of Facial Aging 
Dr. Furlan, Dr. 
Alam (USA) 
 
In 
progress 
- - - 
Core Outcome Set 
for Nail Psoriasis 
Dr. Busard (The 
Netherlands) 
  In progress - - 
Core Outcome Set 
for Chronic 
Spontaneous 
Urticaria 
Dr. Weller 
(Germany) 
 
In 
progress  
- - - 
The Outcomes for 
Pressure Ulcer 
Trials (OUTPUTs) 
project 
Prof. Balzer 
(Germany) 
  In progress - - 
CONSIDER – Core 
Outcome Set in 
IAD Research 
Prof. Beeckman 
(Belgium)   In progress - - 
ACORN- Core 
Outcome Set for 
Acne 
Prof. Thiboutot 
(USA)   In progress - - 
OVAMA – Core 
outcome Set for 
Congenital 
Vascular 
Malformations 
Dr. Horbach 
(The 
Netherlands)    In progress - 
HISTORIC – Core 
Outcome Set for 
Hidranetis 
Suppurativa 
Dr. Thorlacius 
(Denmark) 
 
In 
progress 
- - - 
INFO – Core 
Outcome Set for 
Vitiligo 
Dr. Eleftheriadou 
(UK)    In progress - 
Harmonising 
Outcome Measures 
for Eczema 
(HOME) 
Dr. Chalmers 
(UK) 
     
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BJD-2017-0678R1 
Response to the editor and reviewers 
 
Dear Editors, 
Dear Reviewers, 
 
Thank you very much for you helpful comments for our manuscript which has helped us to improve it 
further. Please find our point-by-point responses below. Changes in the manuscript are underlined. 
 
 
Reviewer: 1 
COMMENTS TO AUTHORS 
Comment: The authors have changed and corrected their manuscript properly. 
However, one added sentence is on my concern: 'The Delphi technique is the current methodological 
standard for outcome domain and outcome measurement instrument selection and prioritization' is 
something that need to be revised, as to my knowledge there is little guidance (Also from COSMIN) if 
the Delphi technique should be used in the measurement instrument selection. I would advise to 
rephrase this sentence to a less conclusive one on what the methodological standards are. 
Response: We agree and relaxed this statement accordingly. 
Changes to manuscript: “The Delphi technique is considered as the current methodological 
standard…” (page 12, line 16) 
 
 
Reviewer: 2 
COMMENTS TO AUTHORS 
Comment 1: While you cite an IDEOM manuscript, it is not clear how many of your members may 
overlap though you indicate work is being done with them on page 16 of 29.  In fact, they have a paper 
published more recently which you may want to cite as the manuscript you cite related to IDEOM is 
from 2015: 
Elman SA, Merola JF, Armstrong AW, Callis Duffin K, Latella J, Garg A, Gottlieb AB:  The 
International Dermatology Outcome Measures (IDEOM) Initiative:  A Review and Update.  J.Drugs 
Dermatol.  16:119-124, 2017. 
Response: Thank you very much for bringing this paper to our attention which we have now added. 
Unfortunately, we do not have exact numbers of researchers who are in which COS projects and 
initiatives involved. 
Changes to manuscript: The reference was added. 
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Comment 2: Line 30, page 7 of 29: You state appropriate ways of patient involvement are not always 
clear.  However, while your statement is somewhat accurate, there is guidance on how to involve 
patients: https://www.eular.org/myUploadData/files/Reference_cards_explained_Booklet_pages_23-
08-13_1.pdf AND 
https://www.eular.org/pare_patient_research_partners.cfm 
I suggest rephrasing your statement to acknowledge the work that has been done to include patient 
research partners in work. 
Response: We agree that work has been done in this area. We added this and we include the reference 
now. 
Changes to manuscript: “Guidance on how to involve patients in research in general35 is available 
and…” (page 13, line 22) 
 
Comment 3: Lines 25-29, page 9 of 29: The OMERACT initiative was the first group to 
systematically develop and promote core outcomes use not just in rheumatology but the field of COS 
development as a whole.  Please revise this sentence to remove ‘in rheumatology’ which as written 
underestimates the value of what OMERACT has accomplished. 
Response: We removed ‘in rheumatology’ 
Changes to the manuscript: “The Outcome Measures in Rheumatoid Arthritis Clinical Trials 
(OMERACT) initiative was the first group to systematically develop and promote core outcomes use.” 
(page 8, line 12) 
 
 
Comment 4: Minor issue: line 42 page 9 of 29: …the field is currently tackling…--it is not just 
currently tackling but ‘continuing to tackle’.  The way this paragraph is phrased makes it seem like 
this is still a relatively new endeavor but in fact it has been happening for almost e.g., 10 years in 
dermatology with the HOME project. It has been happening even longer in rheumatology, but other 
areas include e.g., audiology, pain, rehabilitation. 
Response: This was changed accordingly. 
Changes to manuscript: “… the field is continuing to tackle a …” (page 8, Line 20) 
 
Comment 5: Line 7, page 9 of 29: ‘(that includes patients)’ should be ‘(that include patients)’. 
Response: Changed. 
Changes to manuscript: “… (that include patients) …” (page 8, Line 2). 
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Comment 6. Line 5, page 10 of 29: ‘the HOME roadmap is being used by many COS initiatives 
throughout different medical fields’: the articles cited all have to do with dermatology, not other 
medical fields.  Please revise accordingly (e.g., add other references from other therapeutic areas of 
medicine, or indicate different dermatologic conditions rather than medical fields). 
Response: This was revised. 
Changes to manuscript: “…the HOME roadmap is being used by many COS initiatives in 
dermatology.” (page 9, line 1) 
 
Comment 7. Line 19, page 11 of 29: while ‘The majority was…’ is not incorrect, it is better to use 
‘were’ than ‘was’. 
Response: This was revised. 
Changes to manuscript: “The majority were…” (page 10, line 9) 
 
Comment 8. Line 17, page 12 of 29: I understand if domain identification at the meeting only 
discussed systematic literature reviews, but e.g., focus groups are another way.  Acknowledgement of 
the patient in eliciting these domains that are important are woefully underrepresented and discussed 
in your paper (although the comment that patient and public involvement could have been more 
structured on page 16 of 29 is appreciated).  Clinical trials therefore as mentioned are not the only way 
e.g., to test the domains that may be important. 
Response: We agree that there are several sources for COS domain identification and looking into 
literature is only one way for doing that. Therefore we say in the second sentence: “Systematic 
literature searches are one way for identifying domains.” In order to address the comment we changed 
this statement. 
Changes to manuscript: “In addition to qualitative approaches systematic literature searches are 
another way for identifying domains.” (page 11, line 10). 
 
Comment: 9. Line 40, page 13 of 29: ‘Currently, five and seven item and nine item…’ should be 
rephrased as ‘Currently, five, seven, and nine item…’ 
Response: This was changed. 
Changes to manuscript: “Currently, five, seven, and nine item scales … “ (page 12, line 19). 
 
Comment 10. Line 32, page 14 of 29: this sentence which starts with ‘The way in which results 
are…’ needs revision to make sense.   
Response: This was corrected. 
Changes to manuscript: “The way in which results are presented …“ (page 13, line 15). 
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Comment 11. Page 14 of 29, section on patient involvement.  You mix concepts of patient 
involvement related to patient research partners vs patients that may come from a focus group.  
Particular patient groups may not always be excluded if e.g., focus groups are performed.  In a 
consensus meeting, it is true that the whole universe of patients cannot be captured, but if appropriate 
number of focus groups have been performed then the patient research partner can at least interpret 
those data from the perspective of conducting research.  Please make it clear that there are different 
levels of patient involvement, or alternatively, distinction wasn’t made during the discussion of the 
different levels of patient involvement, e.g. focus groups vs research partner. 
Response: Thank you very much for highlighting this difference. Based on your comment we added a 
sentence. 
Changes to manuscript: “Overall, there is a difference between involving patients in the COS 
development project as partners or as participants (e.g. in a Delphi study).“ (page 14, line 7). 
 
Comment 12. Line 28, page 16 of 29: I think ‘for’ should be ‘or’ beween ‘…(IDEOM) Group for the 
Hidradenitis…’ 
Response: Changed. 
Changes to manuscript: “… The International Dermatology Outcome Measures (IDEOM) Group
37,38 
in the Hidradenitis …“ (page 15, line 13). 
 
Comment 13. Line 19, page 17 of 29: IDEOM is also an international group focused on core 
outcome set development in dermatology.  To say that CSG-COUSIN is the only such group even if 
qualified by exclusive focus is a little self-aggrandizing. Others may be doing it in different ways, but 
they are focused on this too. 
Response: We agree with this comment and changed this statement accordingly. 
Changes to manuscript: “…CSG-COUSIN is an international group with a clear and exclusive focus 
on developing core outcome sets in dermatology …“ (page 16, line 10). 
 
Comment 14. Line 26, page 17 of 29: should invite payers, industry, regulators as well. 
Response: We added this. 
Changes to manuscript: “We invite interested researchers, clinicians, methodologists, patients, 
payers, industry, and regulators to participate …“ (page 16, line 13). 
 
Comment 15. In general, recent literature which is not cited or acknowledge in terms of its 
importance are not mentioned: http://www.nejm.org/doi/full/10.1056/NEJMp1511701#t=article or 
reference within article to ICHOM group since you have a focus on harmonizing outcomes across 
dermatologic conditions. 
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Response: We agree that the Porter et al. and other papers are important for outcome standardization 
in general. However, the focus of the CSG-COUSIN and the meeting was on COS in clinical trials. 
Various concepts are discussed already and we feel that adding another topic might not contribute to 
the overall understanding. 
Changes to manuscript: None. 
 
 
Associate Editor Comments for Authors: 
Comments: Thank you for addressing my review comments. 
Response: Thank you very much. 
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